US FDA Proposes Restrictions on Mass Production of Novo and Lilly Weight-Loss Drugs

GOOGL stock is technically in overbought territory (RSI 71.4), carrying potential for a short-term correction. However, since the news headline is not directly related to Alphabet's operations, the market impact may be limited. Although the MACD still gives a bullish signal, the overbought level and the 3.3% rise in the last 24 hours could trigger profit-taking in the short term. Therefore, no clear directional signal has emerged.

The news suggests imposing restrictions on the mass production of weight-loss drugs, one of Novo Nordisk's key revenue sources. This could negatively impact the company's growth expectations and put pressure on its stock. Technically, while the RSI at 66 is approaching overbought territory, the MACD has just crossed below its signal line, indicating a weakening signal. Short-term selling pressure is likely to increase.

The news suggests restrictions on mass production of LLY's weight-loss drugs, which could limit sales volume in the short term. However, technical indicators point to a strong upward trend: RSI at 64.8 is not yet in overbought territory, MACD is positive, and the price is above both the 20-day and 50-day moving averages. The 2.1% gain in the last session may indicate that the market has not fully priced in the news. Short-term uncertainty is high, with a potential balance between regulatory risk and technical momentum.